Medizinische Universität Graz - Research portal
Selected Publication:
Pakisch, B; Kohek, P; Poier, E; Stücklschweiger, G; Poschauko, J; Raith, J; Quehenberger, F; Mayer, R; Hackl, A.
Iridium-192 high dose rate brachytherapy combined with external beam irradiation in non-resectable oesophageal cancer.
Clin Oncol (R Coll Radiol). 1993; 5(3):154-158
Doi: 10.1016/S0936-6555(05)80314-0
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Mayer Ramona
- Quehenberger Franz
- Raith Johann
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Forty-eight patients with non-resectable cancer of the oesophagus and oesophagogastric junction (group A: Stage I/II: n = 32; group B: Stage III/IV: n = 16) underwent intralumenal iridium-192 high dose-rate afterloading brachytherapy (5-7 Gy/session, total dose 5-21 Gy, mean 12.4 Gy) and external beam irradiation (Karnofsky > or = 80%: 50-60 Gy/2 Gy per day; Karnofsky 60%-79%: 30 Gy/3 per day). Prolonged satisfactory palliation (intake of at least semi-solid food) was demonstrated in 96% of patients. The mean survival for group A was 19.1 months and that for group B 6.9 months, with a 12-month survival rate of 66% for group A and 0% for group B (P < 0.001). Local tumour response and complication rate were significantly dose related with a predicted response rate of 70.5% and a complication rate of 50% at extrapolated response dose (ERD) 129.3 GY3 (Gy at alpha/beta = 3).
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Brachytherapy - adverse effects
- Esophageal Neoplasms - mortality
- Female -
- Humans -
- Iridium Radioisotopes - therapeutic use
- Male -
- Middle Aged -
- Palliative Care -
- Radiotherapy Dosage -
- Survival Rate -